NCT03329885View on ClinicalTrials.gov

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

June 26, 2018

Study Completion Date

June 26, 2018

Conditions
Rheumatoid ArthritisPsoriasisAnkylosing SpondylitisInflammatory Bowel DiseasesNonalcoholic Steatohepatitis
Interventions
DRUG

BMS-986251

Escalating oral dose

OTHER

Placebo

Escalating oral dose

Trial Locations (1)

9728 NZ

Local Institution, Groningen

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03329885 - A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis | Biotech Hunter | Biotech Hunter